La cadena de opciones muestra datos clave de las opciones de acciones de LeddarTech Holdings a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para LeddarTech Holdings..

LeddarTech Holdings (NASDAQ:LDTC) Bolsa, Cadena de Opciones

LeddarTech Holdings

LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation. The company generates the majority of its revenue from France, Canada, and the United states.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARQT

ATPC

BDTX

DRCT

GCTK

ITCI

LAES

LDTC

QBTS

QMMM

RGTI

RIME

SAGE

STAI

TRAW

VMAR

Sage Therapeutics sube 34% tras oferta de Biogen. Conoce los mayores ganadores y perdedores del premercado de EE.UU.

Las acciones de Sage Therapeutics (SAGE) se disparan un 34%; 20 acciones que se mueven en premercado

ACON

AEON

BCTX

CPHC

EKSO

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

KITT

MBOT

MEGL

MNSO

NSTS

SPPL

WFCF

Explora los mayores movimientos en el premercado con ganancias superiores al 100% y pérdidas significativas antes de la apertura.

Acciones de Smart Share Global se disparan un 44%; 20 acciones que se mueven en el premercado

LeddarTech Holdings Inc

HC Wainwright &amp; Co. analyst Oren Livnat reiterates Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) with a Buy and maintains $21 price target.

Price Target

Reiteration

Analyst Ratings

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

HC Wainwright & Co. Reiterates Buy on Avadel Pharmaceuticals, Maintains $21 Price Target

Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 650 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $26.50 million which missed the analyst consensus estimate of $27.29 million by 2.91 percent. This is a 13.41 percent increase over sales of $23.36 million the same period last year.

Earnings

Earnings Misses

YMAB

Y-mAbs Therapeutics Q4 2024 GAAP EPS $(0.15) Misses $(0.12) Estimate, Sales $26.50M Miss $27.29M Estimate

Wells Fargo analyst Praneeth Satish downgrades Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) from Equal-Weight to Underweight and lowers the price target from $4 to $0.5.

Downgrades

NOVA

Wells Fargo Downgrades Sunnova Energy Intl to Underweight, Lowers Price Target to $0.5

Pet Valu Hldgs (CSE2: PET) is looking for FY2025 Adj EPS of $1.60-$1.66 vs $1.61 analyst estimate. sees sales of $1.170 billion-$1.200 billion vs $1.17 billion analyst estimate.

Guidance

Pet Valu Hldgs Sees FY2025 Adj EPS CAD $1.60-$1.66 vs $1.61 Est; Sees Sales CAD $1.170B-$1.200B vs $1.17B Est

"During February, we saw record performance around Valentines Day. However, our topline performance for the month was soft, as uncharacteristically cold weather across the U.S. affected apparel sales, and declining consumer confidence impacted our discretionary assortment overall," said Jim Lee, chief financial officer.&nbsp;
"Looking ahead, we expect to see a moderation in this trend as apparel sales respond to warmer weather around the country, and consumers turn to Target for upcoming seasonal moments such as the Easter holiday. &nbsp;We will continue to monitor these trends and will remain appropriately cautious with our expectations for the year ahead."

Target Expects Meaningful YoY Profit Pressure In Q1 Relative To Remainder Of The Year, In Light Of Ongoing Consumer Uncertainty And Small Decline In February Sales, Combined With Tariff Uncertainty

HC Wainwright &amp; Co. analyst Edward White reiterates TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) with a Buy and maintains $55 price target.

TGTX

HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $55 Price Target

Sea Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/se#NYSE">SE</a>) ("Sea" or the "Company") today announced its financial results for the fourth quarter and full year ended December 31, 2024."We delivered a great 2024 with all three businesses going back to strong,
Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) ("Sea" or the "Company") today announced its financial results for the fourth quarter and full year ended December 31, 2024.
"We delivered a great 2024 with all three businesses going back to strong, double-digit growth, exceeding our original guidance. It was also our second consecutive year of annual positive profit, with all three of our businesses recording positive adjusted EBITDA," said Forrest Li, Sea's Chairman and Chief Executive Officer.
On e-commerce, he said, "GMV grew 28% year-on-year to surpass US$100 billion, and we achieved adjusted EBITDA profitability in both Asia and Brazil. We remain confident about our ability to continue delivering profitable growth in 2025 and expect Shopee's full year 2025 GMV growth to be around 20%, with improving profitability."
Regarding digital financial services, Mr. Li shared, "We delivered exceptional loan book growth of more than 60% year-on-year in the fourth quarter, surpassing US$5 billion as of the end of 2024, making us one of the largest consumer lending businesses in Southeast Asia. While we have scaled fast, risk management remains to be our top operational priority. In 2025, we expect loan book size to grow meaningfully faster than Shopee's GMV annual growth rate, as we improve credit penetration both on- and off-Shopee."
On digital entertainment, Mr. Li said, "2024 was a great year for Garena, marking Free Fire's remarkable comeback with annual bookings growing at 34% year-on-year. Looking ahead into 2025, we will continue scaling our user base and broadening our content offerings. We now expect Garena to grow double digit year-on-year, for both user base and bookings in 2025."

Sea Expects Shopee's 2025 GMV Growth Of ~20% With Improving Profitability And Garena To Grow Double Digit For Both User Base And Bookings

UBS analyst Manav Gupta downgrades Green Plains (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRE#NASDAQ">GPRE</a>) from Buy to Neutral and announces $7 price target.

GPRE

UBS Downgrades Green Plains to Neutral, Announces $7 Price Target

Health Care

General

NNVC

NanoViricides' NV-387 Promises To Be An Effective Drug To Treat Measles

Pet Valu Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PET#TSX">PET</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.40 by 12.5 percent. This is a 16.67 percent decrease over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $295.15 million which beat the analyst consensus estimate of $291.97 million by 1.09 percent. This is a 2.87 percent increase over sales of $286.91 million the same period last year.

Earnings Beats

TSX:PET

Pet Valu Hldgs Q4 Adj CAD $0.45 Beats $0.40 Estimate, Sales CAD $295.15M Beat $291.97M Estimate

The Company has the following expectations for full-year 2025:
<ul>
<li>A modest increase in the Company's operating margin rate compared to full-year 2024</li>
<li>An effective tax rate of 23 to 24 percent</li>
</ul>

Target Expects FY25 Net Sales Growth In Range Around 1%, Reflecting Comparable Sales Growth Around Flat; Adjusted EPS Of $8.80 - $9.80 (Est $9.31)

InfuSystem is providing annual guidance for the full year 2025 with net revenue growth estimated to be in the 8% to 10% range. We are also forecasting Adjusted EBITDA margin (non-GAAP) to be in the high-teens, exceeding the Company's margin of 18.8% in 2024, this despite the planned continued investment in the Company's information technology systems. The Company intends to update its annual guidance throughout the year.&nbsp;

INFU

InfuSystem Estimates 2025 With Net Revenue Growth Of 8% To 10%, With Adjusted EBITDA Margin To Be In The High-Teens

UBS analyst William Grippin downgrades Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) from Buy to Neutral and lowers the price target from $5 to $0.65.

UBS Downgrades Sunnova Energy Intl to Neutral, Lowers Price Target to $0.65

HC Wainwright &amp; Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and maintains $51 price target.

SNDX

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $51 Price Target

Target Reports Q4 Comparable Sales Growth Of 1.5%, Reflected Strong Traffic And Digital Performance

Sea Q4 2024 GAAP EPS $0.39 Misses $0.40 Estimate, Sales $4.950B Beat $4.623B Estimate

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.07 by 42.86 percent. The company reported quarterly sales of $33.85 million which missed the analyst consensus estimate of $34.90 million by 3.02 percent. This is a 6.54 percent increase over sales of $31.77 million the same period last year.

InfuSystems Holdings Q4 2024 GAAP EPS $0.04 Misses $0.07 Estimate, Sales $33.85M Miss $34.90M Estimate

AI Detection firm, Copyleaks has found that the text generated by DeepSeek-R1 and OpenAI&#8217;s ChatGPT has &#8220;Stylistic overlaps&#8221; in 74.2% of instances.
What Happened: A study conducted by Copyleaks showed that Chinese start-up firm, DeepSeek-R1&#8217;s text generation closely mirrored OpenAI&#8217;s style in over 74% of cases. This suggests that DeepSeek may have relied on OpenAI's model during its training without authorization, according to the report.
The study employed three AI classifiers to accurately analyze stylistic fingerprints, allowing for model-specific attribution. This plays a vital role in safeguarding intellectual property and fostering ethical AI development.
DeepSeek and OpenAI did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment. 
Interestingly, the written text produced by most other models was easily identifiable as unique to each one, except DeepSeek. For instance, Microsoft&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Phi-4 and Grok-1 models exhibited no similarities to existing models, confirming it was trained independently.
The majority of DeepSeek&#8217;s outputs were identified as being generated by OpenAI&#8217;s models. &nbsp;&#8220;While this similarity doesn&#8217;t&nbsp;definitively prove or declare DeepSeek&nbsp;as a derivative, it does&nbsp;raise questions about its development,&#8221; said&nbsp;Shai Nisan,&nbsp;Head of data science at&nbsp;Copyleaks.
SEE ALSO: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44075328/eric-trump-says-timing-of-strategic-bitcoin-xrp-cardano-reserve-announcement-was-a-win-for-retail-investors">Eric Trump Says Timing Of Strategic Bitcoin, XRP, Cardano Reserve Announcement Was A &#8216;Win&#8217; For Retail Investors</a>
Why It Matters: This revelation comes at a time when the AI industry is under scrutiny. Recently, Singapore authorities launched an investigation into potential <a href="https://www.benzinga.com/25/03/44076579/singapore-investigates-potential-fraud-in-nvidia-ai-chip-shipments-the-question-is-whether-malaysia-was-a-final-destination">fraudulent activities </a>related to the shipment of&nbsp;Nvidia Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips.
Furthermore,&nbsp;Dario Amodei, CEO of Jeff Bezos-backed Anthropic, has called for stronger U.S. AI safeguards. He warned that autocratic regimes like <a href="https://www.benzinga.com/25/03/44069535/anthropic-ceo-dario-amodei-pushes-for-stronger-us-ai-safeguards-saying-autocracies-like-china-and-russia-could-use-ai-to-expand-their-power">China and Russia </a>could use AI to enhance their control and military capabilities.
While the possibility of both AI models being trained using intersecting datasets cannot be ruled out, there could be deeper nuances. "Even if large language models draw from overlapping datasets, AI fingerprinting remains crucial. The sheer variety of elements—such as architecture, fine-tuning methods and generation techniques—ensures that each LLM develops a distinct writing style,&#8221; explains Nisan.
The DeepSeek-R1 and OpenAI similarity issue underscores the need for clear regulations and transparency in AI development to prevent potential misuse and protect intellectual property. It also brings into question DeepSeek R1&#8217;s perceived level of innovation.
Nisan cautioned that this could have significant implications for the AI industry, if not regulated.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/03/44101621/deepseek-loses-top-spot-as-tencents-yuanbao-ai-becomes-no-1-iphone-app-amid-intensifying-ai-battle">DeepSeek Loses Top Spot As Tencent&#8217;s Yuanbao AI Becomes The Top iPhone App In China Amid Intensifying AI Battle</a></li>
</ul>
Image Via Midjourney, Shutterstock

Equities

Tech

MSFT

NVDA

74% Of DeepSeek's Output Mimics OpenAI's ChatGPT, New Study Reveals: 'It Does Raise Questions About Its Development'

Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) reported quarterly earnings of $2.41 per share which beat the analyst consensus estimate of $2.26 by 6.64 percent. This is a 19.13 percent decrease over earnings of $2.98 per share from the same period last year. The company reported quarterly sales of $30.91 billion which beat the analyst consensus estimate of $30.84 billion by 0.23 percent. This is a 3.15 percent decrease over sales of $31.92 billion the same period last year.

Target Q4 2024 Adj EPS $2.41 Beats $2.26 Estimate, Sales $30.91B Beat $30.84B Estimate

UBS analyst William Grippin downgrades Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) from Buy to Sell and lowers the price target from $37 to $8.

AMRC

UBS Downgrades Ameresco to Sell, Lowers Price Target to $8

Financing

Press Releases

LeddarTech Announces Receipt of the First Installment of the TI Pre-Paid Royalty Fee

LeddarTech to Host Investor and Business Update Call on December 18, 2024

LeddarTech Reports FY24 Results

LeddarTech Showcases LeddarVision Surround-View ADAS AI Platform Technology at CES 2025 in Las Vegas

LeddarTech Reports on Participation in CES 2025

LeddarTech Enters Into Amendments to Credit Facility and Bridge Financing Offer

Contracts

LeddarTech Announces First OEM Design Win for LeddarVision ADAS Solution

LeddarTech Announces Listing Transfer to the Nasdaq Capital Market; Comments on Recent Positive Business Developments

LeddarTech Reports Fiscal First Quarter 2025 Financial Results

Elevating Road Safety and Autonomous Driving: LeddarTech to Demonstrate Innovative Solutions at Three Key European Events

Comments

LeddarTech Holdings

LeddarTech Holdings (LDTC) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL